| ［1］ |
Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine［J］. Clin Exp Rheumatol, 2015,33（5 Suppl 93）:S2⁃S6.<br />
|
| ［2］ |
Dogra S, Mahajan R. Systemic methotrexate therapy for psoriasis: past, present and future［J］. Clin Exp Dermatol, 2013,38（6）:573⁃588. doi: 10.1111/ced.12062.<br />
|
| ［3］ |
Weidmann A, Foulkes AC, Kirkham N, et al. Methotrexate toxicity during treatment of chronic plaque psoriasis: a case report and review of the literature［J］. Dermatol Ther （Heidelb）, 2014,4（2）:145⁃156. doi: 10.1007/s13555⁃014⁃0056⁃z.<br />
|
| ［4］ |
Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate⁃to⁃severe plaque psoriasis: results of an open⁃label, active⁃controlled, randomized trial （RESTORE1）［J］. Br J Dermatol, 2011,165（5）:1109⁃1117. doi: 10.1111/j.1365⁃2133.2011.10615.x.<br />
|
| ［5］ |
Evans WE, McLeod HL. Pharmacogenomics⁃⁃drug disposition, drug targets, and side effects［J］. N Engl J Med, 2003,348（6）:538⁃549. doi: 10.1056/NEJMra020526.<br />
|
| ［6］ |
Maliepaard M, Nofziger C, Papaluca M, et al. Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective［J］. Nat Rev Drug Discov, 2013,12（2）:103⁃115. doi: 10.1038/nrd3931.<br />
|
| ［7］ |
Woolf RT, Smith CH. How genetic variation affects patient response and outcome to therapy for psoriasis［J］. Expert Rev Clin Immunol, 2010,6（6）:957⁃966. doi: 10.1586/eci.10.74.<br />
|
| ［8］ |
Campalani E, Arenas M, Marinaki AM, et al. Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis［J］. J Invest Dermatol, 2007,127（8）:1860⁃1867. doi: 10.1038/sj.jid.5700808.<br />
|
| ［9］ |
Warren RB, Smith RL, Campalani E, et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis［J］. J Invest Dermatol, 2008,128（8）:1925⁃1929. doi: 10.1038/jid.2008.16.<br />
|
| ［10］ |
Bohanec Grabar P, Leandro⁃García LJ, Inglada⁃Pérez L, et al. Genetic variation in the SLC19A1 gene and methotrexate toxicity in rheumatoid arthritis patients［J］. Pharmacogenomics, 2012,13（14）:1583⁃1594. doi: 10.2217/pgs.12.150.<br />
|
| ［11］ |
Owen SA, Hider SL, Martin P, et al. Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients［J］. Pharmacogenomics J, 2013,13（3）:227⁃234. doi: 10.1038/tpj.2012.7.<br />
|
| ［12］ |
van der Schoor LW, Verkade HJ, Kuipers F, et al. New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition［J］. Expert Opin Drug Metab Toxicol, 2015,11（2）:273⁃293. doi: 10.1517/17425255.2015.981152.<br />
|
| ［13］ |
Jones PM, George AM. The ABC transporter structure and mechanism: perspectives on recent research［J］. Cell Mol Life Sci, 2004,61（6）:682⁃699. doi: 10.1007/s00018⁃003⁃3336⁃9.<br />
|
| ［14］ |
Muralidharan N, Misra DP, Jain VK, et al. Effect of thymidylate synthase （TYMS） gene polymorphisms with methotrexate treatment outcome in south Indian Tamil patients with rheumatoid arthritis［J］. Clin Rheumatol, 2017,36（6）:1253⁃1259. doi: 10.1007/s10067⁃ 017⁃3608⁃7.<br />
|
| ［15］ |
Wessels JA, de Vries⁃Bouwstra JK, Heijmans BT, et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single⁃nucleotide polymorphisms in genes coding for folate pathway enzymes［J］. Arthritis Rheum, 2006,54（4）:1087⁃1095. doi: 10.1002/art.21726.<br />
|
| ［16］ |
皮肖冰, 王晓霞, 王继辉, 等. 银屑病亚甲基四氢叶酸还原酶基因多态性与甲氨蝶呤疗效及不良反应的关系［J］. 皮肤性病诊疗学杂志, 2014,21（3）:192⁃196. doi:10.3969/j.issn.1674⁃8468.2014.03.008.<br />
|
| ［17］ |
Shao W, Yuan Y, Li Y. Association between MTHFR C677T polymorphism and methotrexate treatment outcome in rheumatoid arthritis patients: a systematic review and meta⁃analysis［J］. Genet Test Mol Biomarkers, 2017,21（5）:275⁃285. doi: 10.1089/gtmb.2016.0326.<br />
|
| ［18］ |
Spyridopoulou KP, Dimou NL, Hamodrakas SJ, et al. Methylene tetrahydrofolate reductase gene polymorphisms and their association with methotrexate toxicity: a meta⁃analysis［J］. Pharmacogenet Genomics, 2012,22（2）:117⁃133. doi: 10.1097/FPC.0b013e32834ded2a.<br />
|
| ［19］ |
Fisher MC, Cronstein BN. Metaanalysis of methylenetetrahydrofo⁃late reductase （MTHFR） polymorphisms affecting methotrexate toxicity［J］. J Rheumatol, 2009,36（3）:539⁃545. doi: 10.3899/jrheum.080576. <br />
|
| ［20］ |
史天陆, 张永煌, 李宇, 等. 亚甲基四氢叶酸还原酶基因C677T和A1298C多态性与甲氨蝶呤致血液系统不良反应关系的Meta分析［J］. 药物不良反应杂志, 2016,18（5）:321⁃329. doi:10.3760/cma.j.issn.1008⁃5734.2016.05.001.<br />
|
| ［21］ |
Weisman MH, Furst DE, Park GS, et al. Risk genotypes in folate⁃dependent enzymes and their association with methotrexate⁃related side effects in rheumatoid arthritis［J］. Arthritis Rheum, 2006,54（2）:607⁃612. doi: 10.1002/art.21573.<br />
|
| ［22］ |
Lee YH, Bae SC. Association of the ATIC 347 C/G polymorphism with responsiveness to and toxicity of methotrexate in rheumatoid arthritis: a meta⁃analysis［J］. Rheumatol Int, 2016,36（11）:1591⁃1599. doi: 10.1007/s00296⁃016⁃3523⁃2.<br />
|
| ［23］ |
Warren RB, Smith RL, Campalani E, et al. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms［J］. Br J Dermatol, 2009,160（2）:438⁃441. doi: 10.1111/j.1365⁃2133.2008.08898.x. <br />
|
| ［24］ |
Yélamos O, Puig L. Systemic methotrexate for the treatment of psoriasis［J］. Expert Rev Clin Immunol, 2015,11（5）:553⁃563. doi: 10.1586/1744666X.2015.1026894.<br />
|
| ［25］ |
Indhumathi S, Rajappa M, Chandrashekar L, et al. Pharmaco⁃genetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis［J］. Eur J Clin Pharmacol, 2017,73（8）:965⁃971. doi: 10.1007/s00228⁃017⁃2255⁃x.<br />
|
| ［26］ |
West J, Ogston S, Foerster J. Safety and efficacy of methotrexate in psoriasis: a meta⁃analysis of published trials［J/OL］. PLoS One, 2016,11（5）:e0153740［2016⁃05⁃11］. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864230/. doi: 10.1371/journal.pone.0153 740.<br />
|
